|
Sep 25
|
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
|
|
Sep 23
|
Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU
|
|
Sep 6
|
Why Is SpringWorks Therapeutics (SWTX) Up 11.7% Since Last Earnings Report?
|
|
Sep 6
|
Exploring 3 High Growth Tech Stocks in the United States
|
|
Sep 5
|
Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?
|
|
Aug 29
|
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
Jul 30
|
When Will Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Breakeven?
|
|
Jul 25
|
Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Jun 28
|
Sector Update: Health Care Stocks Edge Higher in Afternoon Trading
|
|
Jun 28
|
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
|
|
Jun 19
|
Investors might be losing patience for Apellis Pharmaceuticals' (NASDAQ:APLS) increasing losses, as stock sheds 6.3% over the past week
|
|
May 14
|
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
|
|
May 9
|
Analysts Are Updating Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates After Its First-Quarter Results
|
|
May 8
|
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Apellis Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
May 8
|
Apellis Pharmaceuticals Inc (APLS) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...
|
|
May 7
|
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
|
|
May 7
|
Apellis Pharmaceuticals (APLS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
May 7
|
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 7
|
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
|